Neumora plans clinical trials, data readouts through 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. NVDA
2. DPZ
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. META

Go back to Neumora plans clinical trials, data readouts through 2026

Big Stock Moves on NLRP3 Competitive Landscape News; Positive Read-throughs for Neumora Therapeutics (NMRA) - Mizuho

January 7, 2026 1:20 PM EST

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $6.00 price target on Neumora Therapeutics (NASDAQ: NMRA)

The analyst comets "NMRA shares are +25-30 intraday (vs. +3% XBI) and +50% (vs. +5% XBI) over the past two trading sessions, following we believe recent media... More